Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

C. Pellegrini, A. Broccoli, A. Pulsoni, L. Rigacci, C. Patti, G. Gini, D. Mannina, M. Tani, C. Rusconi, A. Romano, A. Vanazzi, B. Botto, A. Santoro, S. Hoaus, G.M. Rigolin, P. Musto, P. Mazza, S. Molica, P. Corradini, A. FamaF. Gaudio, M. Merli, F. Ronconi, G. Gritti, D. Vallisa, P. Tosi, A.M. Liberati, A. Pinto, V. Pavone, F. Gherlinzoni, M.P. Bianchi, S. Volpetti, L. Trentin, M.C. Goldaniga, M. Bonfichi, A.D. Renzo, C. Schiavotto, M. Spina, A.M. Carella, V. Stefoni, L. Argnani, P.L. Zinzani

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)91703-91710
Number of pages8
Issue number53
Publication statusPublished - 2017


  • brentuximab vedotin
  • CD30 antigen, acute myeloid leukemia
  • adult
  • adult respiratory distress syndrome
  • aged
  • allogeneic stem cell transplantation
  • Article
  • cancer recurrence
  • clinical practice
  • disease free survival
  • disease severity
  • drug dose reduction
  • drug efficacy
  • drug response
  • drug safety
  • drug tolerability
  • female
  • follow up
  • histopathology
  • Hodgkin disease
  • human
  • incidence
  • Italy
  • major clinical study
  • male
  • multiple cycle treatment
  • neutropenia
  • observational study
  • overall survival
  • pancreatitis
  • pancytopenia
  • peripheral neuropathy
  • personal experience
  • progression free survival
  • respiratory failure
  • retrospective study
  • sensory neuropathy
  • thrombocytopenia
  • treatment duration

Cite this